Drugs-for-lipid-regulation

Circulation: Cardiovascular Quality and Outcomes: Published Apr 2024TAKE-HOME MESSAGEThis study used data from the FAST-MI program to examine the effect of lipid-lowering therapy (LLT) (atorvastatin ≥40 mg or equivalent or any combination of a statin and ezetimibe) intensity on long-term mortality in 2258 patients aged 80 years or older who ex...
The Lancet Diabetes & Endocrinology: Published: March, 2024Atherosclerotic cardiovascular disease is a leading cause of death worldwide, and LDL cholesterol is a major causal risk factor.Diabetes substantially increases the risk of atherosclerotic cardiovascular disease.TAKE-HOME MESSAGEIn this participant-level meta-analysis of 19 trials,...
Clinical Gastroenterology and Hepatology: February, 2022The incidence rate of hepatocellular carcinoma (HCC) has been increasing for the last 3 decades. Fatty liver progresses from fat accumulation to inflammation to fibrosis to cirrhosis to cancer. Recent evidence suggests potential clinical benefits of statin in cancer chemoprevention a...
European Heart Journal: September, 2022Cardiovascular (CV) disease (CVD) is the leading cause of morbidity and mortality worldwide, despite continuous improvement of medical treatment, diagnosis, and risk factor control. It has been clearly demonstrated that statin therapy confers significant mortality and morbidity benefits in both the primary...
JAMA Cardiology: Published on November, 2022TAKE-HOME MESSAGEQuestion:  Does vitamin D prevent statin-associated muscle symptoms and reduce statin discontinuation?This study assessed whether vitamin D supplementation (2000 IU of cholecalciferol) would prevent statin-associated muscle symptoms (SAMS) and reduce statin discontinuation in 2083 part...
AHA Journal: Circulation: Published on February, 2023Low-density lipoprotein cholesterol (LDL-C) level is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.TAKE-HOME MESSAGEThis study assessed the relationship...
JAMA Internal MedicineTAKE-HOME MESSAGEThis retrospective study evaluated the association between statin initiation and diabetes progression. Progression of diabetes occurred in significantly more statin users. There was a dose–response relationship with higher-intensity statin use.The study examined 12 years of data on patients covered by the...
STATIN SELECTION   A.      Dosage & Administration At the start dose and following dose titration, rosuvastatin was significantly more effective than atorvastatin at reducing LDL-C and achieving European LDL-C goals in patients with type 2 diabetes.   Key Notes The...
Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most common cholesterol-lowering drugs. RemoveAvailable Brand
American College of Cardiology/American Heart Association Task Force Clinical Practice Guidelines identifies high- intensity and moderate-intensity statin therapy for use in primary and secondary prevention of Cardiovascular disease. When choosing a statin dose, expected LDL reduction is not the only...
UMHS Lipid Therapy Guideline Recommendations (2014) The guidelines showed that Rosuvastatin is the most potent statins with respect to lowering LDL, followed by atorvastatin, pitavastatin, simvastatin and lovastatin. Rosuvastatin 40 mg reducing LDL cholesterol by 63% whereas Atorvastatin 80...
C.      Insulin resistance: Lipophilic statins may have adverse metabolic consequences that include impaired insulin secretion and promotion of insulin resistance. Hydrophilic statins ·        pravastatin improves insulin sensitivity in some patients...